Abstract
Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds
Volume: 11 Issue: 2
Author(s): F. A. Syed, J. H.N. Bett and D. L. Walters
Affiliation:
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Abstract: Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Export Options
About this article
Cite this article as:
A. Syed F., H.N. Bett J. and L. Walters D., Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152911798347007
DOI https://dx.doi.org/10.2174/187152911798347007 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Co-administration of Phycocyanobilin and/or Phase 2-Inducer Nutraceuticals for Prevention of Opiate Tolerance
Current Pharmaceutical Design Efficacy and Safety Outcomes of Short Duration Antiplatelet Therapy with Early Cessation of Aspirin Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Current Cardiology Reviews Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships
Current Medicinal Chemistry Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets A Case of Fingolimod-associated Cryptococcal Meningitis
Current HIV Research Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Development of Dry Powder Inhalers
Recent Patents on Drug Delivery & Formulation Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Bedside Balance Testing in Elderly People
Current Aging Science P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance
Cardiovascular & Hematological Agents in Medicinal Chemistry EDITORIAL [ Inhibition of Glycogenolysis Towards Antidiabetic and Other Therapies (Guest Editor: Laszlo Somsak)]
Mini-Reviews in Medicinal Chemistry Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology GC/MS Profile and <i>In-Vitro</i> α-Glucosidase Inhibitory Activity of Essential Oil of <i>Eucalyptus camaldulensis</i> Dehnh Collected from (Erbil) Iraq
Current Bioactive Compounds Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Generation of Mesenchymal Stem Cells by Blood Cell Reprogramming
Current Stem Cell Research & Therapy